BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib in Achondroplasia, Meeting Primary and Key Secondary Endpoints
BBIO has more than doubled off its 52-week low of $28.325 on elevated volume (3.6× avg).
Summary
BridgeBio Pharma reported positive Phase 3 topline results for oral infigratinib in achondroplasia, meeting primary and key secondary endpoints, and plans regulatory submissions in H2 2026.
Key Events · Product Development and Regulatory · BBIO
-
Positive Phase 3 Topline Results
Oral infigratinib successfully met the primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (p<0.0001) in the PROPEL 3 study for achondroplasia.
-
First Statistically Significant Improvement in Body Proportionality
The study achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, specifically in children younger than 8 years old (p<0.05).
-
Well-Tolerated Safety Profile
Oral infigratinib was well-tolerated with no discontinuations or serious adverse events related to the study drug, and no adverse events associated with FGFR1 or FGFR2 inhibition.
-
Regulatory Submissions Planned
BridgeBio plans to submit New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib in the second half of 2026, leveraging its Breakthrough Therapy Designation.
Analysis · BBIO · Life Sciences
BridgeBio Pharma announced highly positive Phase 3 topline results for oral infigratinib in children with achondroplasia. The PROPEL 3 study successfully met its primary endpoint of change from baseline in annualized height velocity (AHV) and, notably, achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia for children younger than 8 years old. The drug was well-tolerated with no discontinuations or serious adverse events related to the study drug. These strong results, coupled with the drug's Breakthrough Therapy Designation, pave the way for New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in the second half of 2026. The company also plans to accelerate development for hypochondroplasia, indicating confidence in the drug's mechanism and potential across related conditions. This represents a significant advancement for patients and a major positive catalyst for BridgeBio's pipeline.
At the time of this filing, BBIO was trading at $76.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.7B. The 52-week trading range was $28.33 to $84.94. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.